BioCentury | Jul 10, 2019
Distillery Therapeutics

Reducing adipogenesis by fibroadipogenic precursors could treat limb-girdle muscular dystrophy

...cells from accumulating and undergoing adipogenesis. In three patients with LGMD2B, which is caused by DYSF...
...adipogenesis by adipogenic and fibroadipogenic precursors, reduced lipid deposition in the muscles of mice lacking DYSF...
...replacement of muscle and the number of fibroadipogenic precursors in muscle. TARGET/MARKER/PATHWAY: Annexin A2 (ANXA2); dysferlin (DYSF)...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

...associated with the SGCG, SGCA and SGCB genes, respectively, while type 2B is linked to DYSF...
...according to FactSet. Full-year sales were $301 million. Targets: ANO5 - Anoctamin 5; DYSF - Dysferlin...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

...associated with the SGCG, SGCA and SGCB genes, respectively, while type 2B is linked to DYSF...
...Sarepta shares were unchanged in early after-hours trading. Targets: ANO5 - Anoctamin 5; DYSF - Dysferlin...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...1012 total Ph I/II Myonexus Therapeutics Inc. MYO-201 Limb girdle muscular dystrophy type 2B (LGMD2B) Dysferlin (DYSF)...
BioCentury | Nov 17, 2014
Company News

Evotec, Jain Foundation deal

...expanded their 2012 deal to develop a cell-based high throughput screening assay using dysferlin ( DYSF...
...The Jain Foundation is a not-for-profit focused on finding therapies for muscular dystrophies caused by DYSF...
BioCentury | Sep 11, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...in DYSF, a single dose of Velcade bortezomib increased DYSF levels in muscles and sarcolemmal DYSF...
...myoblasts compared with pretreatment baselines. In primary myoblasts harboring Arg555Trp, Gly428Arg or Gly299Arg mutations in DYSF...
...with no treatment. Ongoing work includes testing proteasome inhibitors in myoblasts from patients with other DYSF...
BioCentury | Dec 9, 2013
Company News

Cellular Dynamics, Jain Foundation deal

...create five induced pluripotent stem cell (iPSC) lines from patients with muscular dystrophies caused by dysferlin (DYSF)...
BioCentury | Sep 2, 2013
Company News

Evotec, Jain Foundation deal

...expanded their 2012 deal to develop a cell-based high throughput screening assay using dysferlin ( DYSF...
...The Jain Foundation is a not-for-profit focused on finding therapies for muscular dystrophies caused by DYSF...
BioCentury | Mar 1, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...of DYSF could help treat muscular dystrophy. In human myoblasts with missense mutations in the DYSF...
...myotubule formation. Next steps include proof-of-concept studies evaluating Velcade in patients with missense mutations in DYSF...
BioCentury | Dec 2, 2010
Distillery Therapeutics

Indication: Musculoskeletal disease

...that inhibiting the complement factor system in skeletal muscle could help treat muscle-wasting disorders. In dysferlin (Dysf)-deficient...
...skeletal muscle than those in wild-type mice. Genetic knockout of C3 decreased muscle pathology in Dysf...
Items per page:
1 - 10 of 10